Rasburicase

Generic name
Rasburicase
Brand name
ATC Code
V03AF07
Compare …

Rasburicase

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

  Children Adults
Vd (ml/kg) 110-127 75,8-138
Cl (ml/hr/kg) In children and adolescents approx. 35% higher compared to adults, resulting in lower systemic exposure  3,5 
  Renal elimination is less important route for clearance of  rasburicase.
T1/2 (hr) 15,7-22,5 15,7-22,5

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Prophylaxis and treatment of acute uricaemia
  • Intravenous
    • 1 month up to 18 years
      [2]
      • 0.2 mg/kg/day in 1 dose Infusion in 30 minutes..
      • Duration of treatment:

        Maximum 7 days

      • Apply only immediately before and during initiation of chemotherapy (due to insufficient data on repeated use).

    • Term neonate
      [2]
      • 0.2 mg/kg/day in 1 dose Infusion in 30 minutes..
      • Duration of treatment:

        Maximum 7 days

      • Apply only immediately before and during initiation of chemotherapy (due to insufficient data on repeated use).

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

The risk of hypersensitivity and/or reduced effectiveness is greater in a second course of rasburicase.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ALL OTHER THERAPEUTIC PRODUCTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Antidotes
V03AB15
V03AB14
Iron chelating agents
V03AC03
V03AC02
V03AC01
Detoxifying agents for antineoplastic treatment
V03AF03
V03AF01
Drugs for treatment of hypoglycemia
V03AH01
DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT
V03AF03
V03AF01

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Sanofi Winthrop Industrie, SmPC Fasturtec (EU/1/00/170/001-002) Rev 31;12-08-2024, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose